Metformin in Metastatic Hormone-Sensitive Prostate Cancer Undergoing Androgen Deprivation Therapy: Insights from the STAMPEDE Phase 3 Trial and Contemporary Evidence
Posted inClinical Updates news Oncology Urology

Metformin in Metastatic Hormone-Sensitive Prostate Cancer Undergoing Androgen Deprivation Therapy: Insights from the STAMPEDE Phase 3 Trial and Contemporary Evidence

Comprehensive review of metformin's role in metastatic prostate cancer with ADT highlights STAMPEDE trial's findings: no significant overall survival benefit but metabolic side-effect mitigation. Integration of other RCTs outlines nuanced effects on metabolic syndrome and progression outcomes.
MAGNITUDE final analyses: Niraparib + Abiraterone improves symptoms and delays chemotherapy but not overall survival in HRR‑altered mCRPC
Posted innews Oncology Urology

MAGNITUDE final analyses: Niraparib + Abiraterone improves symptoms and delays chemotherapy but not overall survival in HRR‑altered mCRPC

Final MAGNITUDE results show niraparib combined with abiraterone–prednisone improves radiographic PFS, time to symptomatic progression and delays cytotoxic chemotherapy in HRR‑altered mCRPC (notably BRCA1/2), preserves patient‑reported quality of life, but did not demonstrate a statistically significant overall survival benefit in the primary analysis.
Combining α and β Radiopharmaceuticals in mCRPC: Interim AlphaBet Results Show Feasible Safety and Promising PSA Activity for 177Lu‑PSMA‑I&T plus 223Ra
Posted innews Oncology Urology

Combining α and β Radiopharmaceuticals in mCRPC: Interim AlphaBet Results Show Feasible Safety and Promising PSA Activity for 177Lu‑PSMA‑I&T plus 223Ra

Interim data from the AlphaBet phase 1/2 trial show that combined 177Lu‑PSMA‑I&T and radium‑223 is feasible, with no dose‑limiting toxicities, a recommended radium‑223 dose of 55.0 kBq/kg, and a PSA50 rate of 55% (95% CI 36–72). Hematologic grade ≥3 adverse events were uncommon.
Visual Whole-Body Tumor-Burden Classification via PSMA PET/CT: Advancing Prognostic Stratification and Therapy Response Prediction in Metastatic Hormone-Sensitive Prostate Cancer
Posted innews Oncology Radiology Urology

Visual Whole-Body Tumor-Burden Classification via PSMA PET/CT: Advancing Prognostic Stratification and Therapy Response Prediction in Metastatic Hormone-Sensitive Prostate Cancer

A novel PSMA PET/CT-based tumor-burden classification effectively stratifies metastatic hormone-sensitive prostate cancer patients, predicting response and prognosis with androgen receptor signaling inhibitors, especially second-generation treatments.